BDC Capital

BDC Capital Inc. is the private equity and venture capital division of the Business Development Bank of Canada, focusing on direct investments and fund of funds strategies. The firm specializes in providing risk capital to small and medium-sized enterprises, including subordinate financing, recapitalizations, and mezzanine investments. BDC Capital's venture capital activities encompass a wide range of stages from seed funding to pre-IPO financing, with a particular emphasis on technology-based companies in sectors such as healthcare, information technology, and clean technology. It aims to support women-led businesses and typically invests between CAD 3 million and CAD 35 million, taking minority stakes in its portfolio companies. BDC Capital seeks to exit investments within three to five years through various strategies, including initial public offerings or strategic sales. Established in 1975 and headquartered in Montreal, the firm has a presence in key Canadian provinces, actively participating in syndicates and maintaining a focus on high-growth potential companies.

Trevor Allibon

MD, Growth and Transition Capital

Tim April

Managing Director, Fund Investments

Michèle Arsenault

Director, Growth and Transition Capital

Réjean Asselin

Assistant Vice President, Portfolio Management - Growth & Transition Capital

Nicolas Beaudet

Director, Growth and Transition Capital

Amine Benmoussa

Principal

Jeremy Billan

Director of Growth Equity–Growth and Transition Capital

Mike Blattman

Director, Growth and Transition Capital

Charles Blouin

Director, Growth and Transition Capital

Ela Borenstein

vice_president

Laura-Lee Brenneman

Director, Growth and Transition Capital

Jean Bédard

Director of Growth Equity- Growth and Transition Capital

Cyril Cochrane

MD, Growth and Transition Capital

Cheri Corbett

Director

Sean Crouse

Director, Growth and Transition Capital

Robert Dennison

Director of Growth and Transition Capital

Geoff Devereux

Director of Growth and Transition Capital

Pascal Dion

Director, Growth and Transition Capital

Isabelle Dionne

Director, Growth and Transition Capital

Étienne Drouin

MD, Growth and Transition Capital

Martin Dudaniec

Director of Growth and Transition Capital

Robert Duffy

VP of Growth and Transition Capital

Kyle Feucht

Director

Carolyn Galbraith

Director, Growth and Transition Capital

Eric Girard

Director, Growth and Transition Capital

Jonathan Goodkey

Principal

Tony Gopaul

Director, Growth and Transition Capital

Jerome Hamilton

Director of Growth and Transition Capital

Matthew Hanson

Director of Growth and Transition Capital

Neal Hill

VP of Market Development

Christina Howard

Director, Growth and Transition Capital

Barry R. Hubich

VP of Growth and Transition Capital

Emmanuelle Héroux

Director, Growth and Transition Capital

Louis-David Julien

MD, Growth and Transition Capital

Marvin Junop

Director, Growth and Transition Capital

Rita Kasparian

Director, Growth and Transition Capital

Matthew Kellow

VP of Growth and Transition Capital

Karim Kennedy

Director - Cleantech Practice

Siddartha Krishnan

Partner

Enes Kula

Director, Growth and Transition Capital

Larry Lam

Partner, ICE Technology Venture Fund

Louise Langevin

VP, Growth and Transition Capital

Philippe Lapierre

Director, Growth and Transition Capital

Scott Lewis

MD of Growth and Transition Capital

Tabreez Lila

Director, Growth and Transition Capital

Mark Lunick

Director, Growth and Transition Capital

Vern Malcolm

Director Growth and Transition Capital

Bernard Melameth

Director, Growth and Transition Capital

Benoit Mignacco

Vice-President, Portfolio Management - Growth Capital and Business Transfer

Simon F. Mills

Director of Growth and Transition Capital

Claude Miron

Vice-President, Growth Equity

Alison Nankivell

vice_president

Mark O'Connor

Director, Growth and Transition Capital

Ted Olak

Director of Growth and Transition Capital

Denisia Pereira

Principal

Matt Price

MD of Growth and Transition Capital

Joseph Regan

Managing Partner

Mathieu Rinaldi

Director of BDC Growth and Transition Capital

James Robertson

Director of Growth and Transition Capital

Duncan Robinson

Director of Growth and Transition Capital

Susan Rohac

VP of Subordinate Financing

Paul Ryan

Director, Growth & Transition Capital

Syed Saif

Associate

Marie Salama

Assistant VP, Portfolio Management – Growth and Transition Capital

Robert Shaw

Director, Growth and Transition Capital

Conor Snape

Director of Growth and Transition Capital

Marie-Josée Tremblay

Director, Growth and Transition Capital

Brett Weese

Director of Growth and Transition Capital

Brian G. Whiteway

Director, Growth and Transition Capital

Roger Wilson

Assistant VP, Growth and Transition Capital Portfolio

Angelo Zeni

MD of Growth and Transition Capital

Past deals in Ontario

Clearwater Clinical Limited, founded in 2004 and based in Ottawa, Canada, specializes in the design and manufacture of mobile medical-grade devices aimed at enhancing clinical practices in the endoscopy and audiology markets. The company offers innovative products such as ClearSCOPE, a mobile endoscope adaptor that supports various medical applications, including ENT and urology exams, as well as veterinary and industrial uses. Additionally, Clearwater Clinical produces ShoeBOX, an iPad-based audiometer designed for screening and diagnostic testing in diverse settings such as clinics, schools, and telemedicine applications. Another key product is DizzyFIX, which facilitates the Epley Maneuver, a common treatment for vertigo caused by benign paroxysmal positional vertigo. The company, led by Dr. Matthew Bromwich and his team, is committed to providing affordable solutions that leverage mobile technology to improve patient care.

Clearwater Clinical Limited

Venture Round in 2014
Clearwater Clinical Limited, founded in 2004 and based in Ottawa, Canada, specializes in the design and manufacture of mobile medical-grade devices aimed at enhancing clinical practices in the endoscopy and audiology markets. The company offers innovative products such as ClearSCOPE, a mobile endoscope adaptor that supports various medical applications, including ENT and urology exams, as well as veterinary and industrial uses. Additionally, Clearwater Clinical produces ShoeBOX, an iPad-based audiometer designed for screening and diagnostic testing in diverse settings such as clinics, schools, and telemedicine applications. Another key product is DizzyFIX, which facilitates the Epley Maneuver, a common treatment for vertigo caused by benign paroxysmal positional vertigo. The company, led by Dr. Matthew Bromwich and his team, is committed to providing affordable solutions that leverage mobile technology to improve patient care.